{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T06:50:39Z","timestamp":1648709439962},"reference-count":53,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2006,10,1]],"date-time":"2006-10-01T00:00:00Z","timestamp":1159660800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica"],"published-print":{"date-parts":[[2006,10]]},"DOI":"10.1157\/13092470","type":"journal-article","created":{"date-parts":[[2006,9,20]],"date-time":"2006-09-20T06:46:36Z","timestamp":1158734796000},"page":"518-526","source":"Crossref","is-referenced-by-count":2,"title":["Tratamiento de las hepatitis v\u00edricas (II). Tratamiento de la hepatitis cr\u00f3nica C"],"prefix":"10.1016","volume":"24","author":[{"given":"Armando","family":"S\u00e1nchez-Quijano","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eduardo","family":"Lissen-Otero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1157\/13092470_bib1","first-page":"341","article-title":"Hepatitis C global prevalence","volume":"72","year":"1997","journal-title":"Weekly Epidemiological Record"},{"key":"10.1157\/13092470_bib2","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1046\/j.1365-2893.1999.6120139.x","article-title":"Report of a WHO consultation organized with the Viral Hepatitis Prevention Board, Antwerp, Belgium","volume":"6","year":"1999","journal-title":"J Viral Hepat"},{"key":"10.1157\/13092470_bib3","first-page":"18","article-title":"Hepatitis C global prevalence (update)","volume":"3","year":"2000","journal-title":"Weeckly Epidemiological Record"},{"key":"10.1157\/13092470_bib4","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1056\/NEJM199212313272702","article-title":"The natural history of community acquired hepatitis C in the United States","volume":"327","author":"Alter","year":"1992","journal-title":"N Engl J Med"},{"key":"10.1157\/13092470_bib5","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1002\/hep.510260233","article-title":"Epidemiological factors affecting the severity of hepatitis C virus-related liver disease: a French survey of 6664 patients","volume":"26","author":"Roudot-Thoraval","year":"1997","journal-title":"Hepatology"},{"key":"10.1157\/13092470_bib6","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1056\/NEJM199606273342601","article-title":"The risk of transfusion-transmitted viral infections","volume":"334","author":"Schreiber","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1157\/13092470_bib7","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1111\/j.1365-2796.1994.tb00838.x","article-title":"Heterosexual transmission of hepatitis C virus and the possible role of coexistent human immunodeficiency virus infection in the index case: a multicentre study of 423 pairings","volume":"236","author":"Soto","year":"1994","journal-title":"J Intern Med"},{"key":"10.1157\/13092470_bib8","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1056\/NEJM199403173301103","article-title":"Transmission of hepatitis C virus from mothers to infants. The Vertical Transmission of Hepatitis C Virus Collaborative Study Group","volume":"330","author":"Ohto","year":"1994","journal-title":"N Engl J Med"},{"key":"10.1157\/13092470_bib9","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0168-8278(97)80275-9","article-title":"Unexpected high prevalence of hepatitis C virus genotype 4 in Southern Spain","volume":"27","author":"S\u00e1nchez-Quijano","year":"1997","journal-title":"J Hepatol"},{"key":"10.1157\/13092470_bib10","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/S0140-6736(96)07642-8","article-title":"Natural history of liver fibrosis progression in patients with chronic hepatitis C","volume":"349","author":"Poynard","year":"1997","journal-title":"Lancet"},{"key":"10.1157\/13092470_bib11","doi-asserted-by":"crossref","first-page":"105","DOI":"10.7326\/0003-4819-132-2-200001180-00003","article-title":"45-years follw-up of hepatitis C virus infection in healthy young adults","volume":"132","author":"Seeff","year":"2000","journal-title":"Ann Intern Med"},{"key":"10.1157\/13092470_bib12","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.jhep.2005.11.009","article-title":"Natural history and predictors of disease severity in chronic hepatitis C","volume":"44","author":"Massard","year":"2006","journal-title":"J Hepatol"},{"issue":"Suppl 1","key":"10.1157\/13092470_bib13","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1002\/hep.21065","article-title":"Hepatitis C \u2013 Identifygin Ptients with Progressive Liver Injury","volume":"43","author":"Feld","year":"2006","journal-title":"Hepatology"},{"key":"10.1157\/13092470_bib14","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/S0168-8278(98)80001-9","article-title":"Impact of HBV, HCV and GBV\/HGV on hepatocellular carcinomas in Europe. Results of a European concerted action","volume":"29","author":"Brechot","year":"1998","journal-title":"J Hepatol"},{"issue":"RR-19","key":"10.1157\/13092470_bib15","first-page":"1","article-title":"Recommendations for prevention and control of Hepatitis C (HCV) Virus Infection and HCV related chronic disease","volume":"47","year":"1998","journal-title":"MMWR"},{"key":"10.1157\/13092470_bib16","unstructured":"National Institutes of Health Consensus Development Conference Statement. Management of hepatitis C: 2002. June; 10-12, 2002. Final Statement. Revisions made on September 12, 2002. Disponible en: http:\/\/consensus.nih. gov\/2002\/2002HepatitisC2002116html.htm Visitado el 6 de abril 2006"},{"key":"10.1157\/13092470_bib17","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1002\/hep.510310332","article-title":"The past incidence of hepatitis C virus infection: implications for the future burden of chronic liver disease in the United States","volume":"31","author":"Armstron","year":"2000","journal-title":"Hepatology"},{"key":"10.1157\/13092470_bib18","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1002\/hep.20119","article-title":"AASLD Practice Guideline. Diagnosis, Management and Treatment of Hepatitis C","volume":"39","author":"Strader","year":"2004","journal-title":"Hepatology"},{"key":"10.1157\/13092470_bib19","unstructured":"National Hepatitis C Program Office Hepatitis C Technical Advisory Group. Department of Veterans Affairs. Treatment Recommendations for Patients with Chronic hepatitis C. September 2003. Version 5.0. Disponible en: http:\/\/www.hepatitis.va.gov\/vahep?page = tp03-01-04-32. Visitado el 5 de abril de 2006"},{"key":"10.1157\/13092470_bib20","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1002\/hep.21046","article-title":"Noninvasive Mesasures of Liver Fibrosis","volume":"43","author":"Rockey","year":"2006","journal-title":"Hepatology"},{"key":"10.1157\/13092470_bib21","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1002\/hep.20518","article-title":"Persistence of hepatitis C virus in patients successfully treated for chronic hepatitis C","volume":"41","author":"Radkoski","year":"2005","journal-title":"Hepatology"},{"key":"10.1157\/13092470_bib22","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1053\/gast.2002.33023","article-title":"Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C","volume":"122","author":"Poynard","year":"2002","journal-title":"Gastroenterology"},{"key":"10.1157\/13092470_bib23","series-title":"Program and abstract of the 56th Annual Meeting of the American Association for the Study of Liver Diseases","article-title":"Hepatic function improves after sustained virologic response in hepatitis C patientes with advanced fibrosis and cirrhosis: results of the lead-in phase of the HALT-C trial","author":"Everson","year":"2005"},{"key":"10.1157\/13092470_bib24","series-title":"Program and abstract of the 56th Annual Meeting of the American Associa tion for the Study of Liver Diseases","article-title":"Long term outcome of patients with HCV-related Child's class A cirrhosis treated with interferon alpha (IFN). The impact of sustained virologic response (SVR) on hepatocellular carcinoma (HCC) occurrence and mortality","author":"Bruno","year":"2005"},{"key":"10.1157\/13092470_bib25","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1016\/0016-5085(94)90131-7","article-title":"A pilot study of combination therapy with ribavirina plus interferon for interferon alfa-resistant chronic hepatitis C","volume":"107","author":"Brillanti","year":"1994","journal-title":"Gastroenterology"},{"key":"10.1157\/13092470_bib26","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1056\/NEJM199811193392101","article-title":"Interferon alfa-2b alone or in combination with ribavirina as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group","volume":"339","author":"McHutchison","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1157\/13092470_bib27","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1016\/S0140-6736(98)07124-4","article-title":"Randomised trial of interferon alfa-2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alfa2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT)","volume":"353","author":"Poynard","year":"1998","journal-title":"Lancet"},{"key":"10.1157\/13092470_bib28","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1056\/NEJMoa020047","article-title":"Peginterferon alpha 2a plus ribavirina for chronic hepatitis C virus infection","volume":"347","author":"Fried","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1157\/13092470_bib29","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/S0140-6736(01)06102-5","article-title":"Peginterferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomnised trial","volume":"358","author":"Manns","year":"2001","journal-title":"Lancet"},{"key":"10.1157\/13092470_bib30","doi-asserted-by":"crossref","first-page":"346","DOI":"10.7326\/0003-4819-140-5-200403020-00010","article-title":"PEGASYS International Study Group. Peginterferon-alfa2a and Ribavirin Combination therapy in Chronic hepatitis C. A randomized Study of Treatment Duration and Ribavirin Dose","volume":"140","author":"Hadziyannis","year":"2004","journal-title":"Ann Intern Med"},{"key":"10.1157\/13092470_bib31","first-page":"1609","article-title":"Peginterferon Alfa-2b and Ribavirin for 12 vs. 24 weeks in HCV Genotype 2 or 3","volume":"325","author":"Mangia","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1157\/13092470_bib32","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.jhep.2003.12.014","article-title":"The impact of peginterferon alpha-2a plus ribavirina combination therapy on health-quality of life in chronic hepatitis C","volume":"40","author":"Hassanein","year":"2004","journal-title":"J Hepatol"},{"key":"10.1157\/13092470_bib33","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.dld.2004.06.011","article-title":"Natural History of Initially Mild Chronic hepatitis C","volume":"36","author":"Alberti","year":"2004","journal-title":"Dig Liver Dis"},{"key":"10.1157\/13092470_bib34","doi-asserted-by":"crossref","unstructured":"EASL International Consensus Conference on Hepatitis C: Paris 26-28, February 1999, consensus statement. J Hepatol. 1999;30:956-61.","DOI":"10.1016\/S0168-8278(99)80154-8"},{"key":"10.1157\/13092470_bib35","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1056\/NEJM200107053450107","article-title":"Hepatitis C Virus Infection","volume":"345","author":"Lauer","year":"2001","journal-title":"N Engl J Med"},{"issue":"Suppl 2","key":"10.1157\/13092470_bib36","first-page":"A21","article-title":"Sustained viral response improves survival in patients with either compensated or decompensated hepatitis C","volume":"42","author":"Cecil","year":"2005","journal-title":"J Hepatol"},{"key":"10.1157\/13092470_bib37","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.idc.2006.01.010","article-title":"Treatment of relapsers after combination therapy for chronic hepatitis","volume":"20","author":"Ahmed","year":"2006","journal-title":"Infect Dis Clin North Am"},{"issue":"Suppl 2","key":"10.1157\/13092470_bib38","first-page":"A603","article-title":"Peginterferon alfa-2a (40 kD) plus ribavirin in chronic hepatitis C patients who failed previous interferon-based therapy: results of a multicentre open-label expanded access program in Canada","volume":"42","author":"Sherman","year":"2005","journal-title":"J Hepatol"},{"key":"10.1157\/13092470_bib39","first-page":"A588","article-title":"Peginterferon alfa-2a (40 kD) plus ribavirin is as effective in patients relapsing after conventional interferon based therapy than in naive patients: results from the BERNAR-1 trial","volume":"42","author":"Nevens","year":"2005","journal-title":"J Hepatol"},{"key":"10.1157\/13092470_bib40","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1056\/NEJM199811193392102","article-title":"International Hepatitis Interventional theraphy Group. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C","volume":"339","author":"Davis","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1157\/13092470_bib41","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1053\/j.gastro.2004.01.014","article-title":"Hepatitis C Antiviral Long-term Treatment Against Cirrhosis Trial Group. Peginterferon alfa-2a and Ribavirin in patients with chronic hepatitis C who have failed prior treatment","volume":"126","author":"Shiffman","year":"2004","journal-title":"Gastroenterology"},{"issue":"Suppl 2","key":"10.1157\/13092470_bib42","first-page":"A96","article-title":"Sustained virologic response (SVR) in the EPIC3 trial: week twelve virology predicts SVR in previous interferon\/ribavirin treatment failures receiving peg-intron\/rebetol (PR) weight-based dosing (WBD)","volume":"42","author":"Poynard","year":"2005","journal-title":"J Hepatol"},{"key":"10.1157\/13092470_bib43","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1002\/hep.510300409","article-title":"Liver fibrosis progression in HIV-HCV coinfected patients. The Multivirc Group","volume":"30","author":"Benhamou","year":"1999","journal-title":"Hepatology"},{"key":"10.1157\/13092470_bib44","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0168-8278(97)80001-3","article-title":"Humman immunodeficiency virus infection modifies the natural history of chronic parenterally-acquired hepatitis C with an unusually rapid progression to cirrhosis","volume":"26","author":"Soto","year":"1997","journal-title":"J Hepatol"},{"key":"10.1157\/13092470_bib45","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/j.jhep.2005.01.022","article-title":"Liver disease as a major cause of death among HIV infected patients: role of hepatitis C an B viruses and alcohol","volume":"42","author":"Salmon-Cer\u00f3n","year":"2005","journal-title":"J Hepatol"},{"key":"10.1157\/13092470_bib46","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1086\/425360","article-title":"Hepatitis C virus co-infection increases mortality in HIV patients in the highly active antiretroviral therapy er: data from the HIV Atlanta cohort study","volume":"39","author":"Anderson","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1157\/13092470_bib47","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.jhep.2005.11.008","article-title":"Natural History and predictors of severity of chronic hepatitis C virus (HCV) and human immunodeficiency virus (HIV) co-infection","volume":"44","author":"Vallet-Pichard","year":"2006","journal-title":"J Hepatol"},{"key":"10.1157\/13092470_bib48","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1086\/499055","article-title":"Do type and duration of antiretroviral therapy attenuate liver fibrosis uin IV-hepatitis C virus-coinfected patients?","volume":"42","author":"Verma","year":"2006","journal-title":"Clin Infect Dis"},{"key":"10.1157\/13092470_bib49","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/j.jhep.2005.03.003","article-title":"(The ECC Jury). Short Statement of the First European Consensus Conference on the Treatment of Chronic Hepatitis B and C in HIV Co-Infected Patients","volume":"42","author":"Alberti","year":"2005","journal-title":"J Hepatol"},{"key":"10.1157\/13092470_bib50","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1056\/NEJMoa040842","article-title":"Peginterferon alfa-2a plus Ribavirin for Chronic hepatitis C Virus infection in HIV-Infected Patients","volume":"351","author":"Torriani","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1157\/13092470_bib51","doi-asserted-by":"crossref","first-page":"2839","DOI":"10.1001\/jama.292.23.2839","article-title":"for the ANRS HC02 RIBAVIC Study Team. Pegylated interferon alfa-2b vs standard interferon alfa-2b plus ribavirina, for chronic hepatitis C in HIV-infected patients. A randomized controlled trial","volume":"292","author":"Carrat","year":"2004","journal-title":"JAMA"},{"key":"10.1157\/13092470_bib52","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1056\/NEJMoa032653","article-title":"Peginterferon alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirina for chronic hepatitis C in HIV-coinfected persons","volume":"351","author":"Chung","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1157\/13092470_bib53","unstructured":"Hepatitis C. New Drugs Pipeline. Drugs specifics for Hepatitis C. Disponible en: http:\/\/www.frontiernet.net\/\u223cmonty\/hcvpipel.html. Visitado el 11 de abril de 2006."}],"container-title":["Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0213005X06738459?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0213005X06738459?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,4,21]],"date-time":"2019-04-21T03:39:10Z","timestamp":1555817950000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0213005X06738459"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,10]]},"references-count":53,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2006,10]]}},"alternative-id":["S0213005X06738459"],"URL":"https:\/\/doi.org\/10.1157\/13092470","relation":{},"ISSN":["0213-005X"],"issn-type":[{"value":"0213-005X","type":"print"}],"subject":[],"published":{"date-parts":[[2006,10]]}}}